CN116964074A - 调节vegf的肽 - Google Patents

调节vegf的肽 Download PDF

Info

Publication number
CN116964074A
CN116964074A CN202180094870.8A CN202180094870A CN116964074A CN 116964074 A CN116964074 A CN 116964074A CN 202180094870 A CN202180094870 A CN 202180094870A CN 116964074 A CN116964074 A CN 116964074A
Authority
CN
China
Prior art keywords
arg
group
peptide
leu
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180094870.8A
Other languages
English (en)
Chinese (zh)
Inventor
圣地亚哥·埃斯特班·马丁
劳拉·内沃拉
米格尔·雷蒙·莫雷诺·拉哈
玛利亚·费尔南达·蒙特纳哥·阿尔塞
宙斯·尼普诺·罗德里格斯·洛佩兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDP Discovery Pharma SL
Original Assignee
IDP Discovery Pharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IDP Discovery Pharma SL filed Critical IDP Discovery Pharma SL
Publication of CN116964074A publication Critical patent/CN116964074A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
CN202180094870.8A 2020-12-29 2021-12-29 调节vegf的肽 Pending CN116964074A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20383169.8 2020-12-29
EP20383169.8A EP4023295A1 (en) 2020-12-29 2020-12-29 Vegf-regulating peptides
PCT/EP2021/087804 WO2022144401A1 (en) 2020-12-29 2021-12-29 Vegf-regulating peptides

Publications (1)

Publication Number Publication Date
CN116964074A true CN116964074A (zh) 2023-10-27

Family

ID=74194498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180094870.8A Pending CN116964074A (zh) 2020-12-29 2021-12-29 调节vegf的肽

Country Status (8)

Country Link
US (1) US20240083943A1 (https=)
EP (2) EP4023295A1 (https=)
JP (1) JP2024503597A (https=)
KR (1) KR20230127272A (https=)
CN (1) CN116964074A (https=)
AU (1) AU2021416274A1 (https=)
CA (1) CA3206857A1 (https=)
WO (1) WO2022144401A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765378B1 (en) * 2004-07-12 2014-04-16 Medical Research Fund of Tel Aviv Sourasky Medical Center Agent capable of downregulating an msf-a-dependent hif-1a and use thereof in cancer treatment
US20120115783A1 (en) * 2008-09-22 2012-05-10 Alleron therapeutics, Inc Peptidomimetic macrocycles
WO2014138429A2 (en) * 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha

Also Published As

Publication number Publication date
JP2024503597A (ja) 2024-01-26
AU2021416274A1 (en) 2023-08-10
EP4023295A1 (en) 2022-07-06
EP4271480A1 (en) 2023-11-08
KR20230127272A (ko) 2023-08-31
WO2022144401A1 (en) 2022-07-07
CA3206857A1 (en) 2022-07-07
AU2021416274A9 (en) 2023-08-24
US20240083943A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
JP7573401B2 (ja) 多リガンド－薬物複合体及びその使用
US12528846B2 (en) BH4 stabilized peptides and uses thereof
AU2021203397A1 (en) Peptides with anti-cancer activity
JP2025131623A (ja) メラノサイト調節ペプチド
CN116964074A (zh) 调节vegf的肽
JP2020529437A (ja) 抗がんペプチド
CN111263768B (zh) 抗癌肽
JP2020529429A (ja) 抗がんペプチド
CA3017424C (en) Peptides with anti-cancer activity
HK40030479A (en) Anticancer peptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination